Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for ccRCC and Synthetic Lethality Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PBRM1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PBRM1 Bromodomain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PBRM1 Products |
| Gene Delivery | PBRM1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PBRM1 Products |
| Benchmark Ab | Anti-PBRM1 Recombinant positive control for assay validation. |
View PBRM1 Products |
| Validator | PBRM1 siRNA Set For knockdown verification and isogenic model creation. |
View PBRM1 Products |
| Related Target A | BRD9 Synthetic lethal partner in SWI/SNF complex. |
View BRD9 Products |
| Related Target B | SMARCA4 Core ATPase of the SWI/SNF complex. |
View SMARCA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Bromodomain Selectivity Screening | Isolated Bromodomain proteins with >95% purity and verified theoretical MW |
| Modeling Loss-of-Function | High-efficiency siRNA and Lentiviral systems for creating stable knockdown lines |
| Lack of Reliable Controls | Sequence-verified recombinant antibodies for consistent IHC/Western blotting |
| False Positives in Screening | Endotoxin-controlled (<1EU/ug) reagents for cell-based assay integrity |
Live PBRM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for targeting SWI/SNF complex vulnerabilities is intensifying. PBRM1 (Polybromo 1) is frequently mutated in clear cell renal cell carcinoma (ccRCC) and acts as a major tumor suppressor. Because restoring a lost tumor suppressor is challenging, the global R&D landscape has heavily shifted toward synthetic lethality—targeting other SWI/SNF components (like BRD9 or SMARCA4) or utilizing PBRM1 loss as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) responsiveness.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Synthetic Lethality (BRD9, PARP) | ccRCC, Solid Tumors | Selectivity Assay (Need high-purity related Bromodomain proteins) |
| Targeted Protein Degrader (PROTAC) | SWI/SNF Degradation | Advanced Carcinomas | Degradation kinetics (Need reliable knockdown models and Abs) |
| Immunotherapy Combo | PD-1/PD-L1 Checkpoint | PBRM1-mutant ccRCC | Biomarker Validation (Need accurate diagnostic antibodies) |